Molecular testing is important to selecting patients with advanced non-small cell lung cancer (NSCLC) who may benefit from targeted therapy or immunotherapy. touchONCOLOGY spoke to Professor Fred Hirsch (The Mount Sinai Hospital, New York City, NY, USA) to discuss his presentation at the European Lung Cancer Congress 2022, providing an update on the current state of personalized medicine and molecular testing in lung cancer.
Questions
- How well has molecular testing been implemented into clinical practice? 00:24-04:15
- What challenges and unmet needs remain? 04:15-07:20
Speaker Disclosure: Fred Hirsch is a member of the advisory board for: Amgen, AstraZeneca/Daiichi,Bristol-Myers, Novartis, NextCure, Novocure, Nectin Therapeutics, Sanofi/Regeneron and OncoCyteSquibb.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the European Lung Cancer Congress 2022
